JP2016518379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518379A5 JP2016518379A5 JP2016509434A JP2016509434A JP2016518379A5 JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5 JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- composition according
- sulfolobus
- variant
- fold protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000499 gel Substances 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 241000205095 Sulfolobus shibatae Species 0.000 claims 2
- 241000205091 Sulfolobus solfataricus Species 0.000 claims 2
- 241000160715 Sulfolobus tokodaii Species 0.000 claims 2
- 229940047122 interleukins Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 101100498534 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) dbp-7 gene Proteins 0.000 claims 1
- 102000043276 Oncogene Human genes 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 101000844743 Saccharolobus shibatae DNA-binding protein 7a Proteins 0.000 claims 1
- 101000844742 Saccharolobus shibatae DNA-binding protein 7b Proteins 0.000 claims 1
- 101000844745 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) DNA-binding protein 7a Proteins 0.000 claims 1
- 101000844752 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) DNA-binding protein 7d Proteins 0.000 claims 1
- 241000205098 Sulfolobus acidocaldarius Species 0.000 claims 1
- 101000844753 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) DNA-binding protein 7d Proteins 0.000 claims 1
- 101000844750 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) DNA-binding protein 7e Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000058 anti acne agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124340 antiacne agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003908 antipruritic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 239000003410 keratolytic agent Substances 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR13/53662 | 2013-04-22 | ||
| FR1353662A FR3004650B1 (fr) | 2013-04-22 | 2013-04-22 | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| PCT/EP2014/058139 WO2014173899A1 (fr) | 2013-04-22 | 2014-04-22 | Compositions topiques comprenant des variantes de pli-ob |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022358A Division JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Ｏｂフォールド変異体を含む局所用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518379A JP2016518379A (ja) | 2016-06-23 |
| JP2016518379A5 true JP2016518379A5 (enExample) | 2017-06-15 |
Family
ID=48795734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509434A Pending JP2016518379A (ja) | 2013-04-22 | 2014-04-22 | Ｏｂフォールド変異体を含む局所用組成物 |
| JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Ｏｂフォールド変異体を含む局所用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019022358A Pending JP2019112410A (ja) | 2013-04-22 | 2019-02-12 | Ｏｂフォールド変異体を含む局所用組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10548945B2 (enExample) |
| EP (1) | EP2988766B1 (enExample) |
| JP (2) | JP2016518379A (enExample) |
| CN (2) | CN111467477A (enExample) |
| ES (1) | ES2637421T3 (enExample) |
| FR (1) | FR3004650B1 (enExample) |
| WO (1) | WO2014173899A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| FR3027521B1 (fr) * | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
| EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| EP3632924A1 (en) | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
| WO2020231504A1 (en) | 2019-05-16 | 2020-11-19 | Massachusetts Institute Of Technology | Glycan-binding proteins and related compositions and methods |
| EP3878858A1 (en) | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| EP4043481A1 (en) | 2021-02-15 | 2022-08-17 | Affilogic | Compounds and methods for extending half life of biomolecules |
| JP2024513711A (ja) | 2021-03-18 | 2024-03-27 | アフィロジック | 抗ｃ３因子ｓａｃ７ｄバリアントおよびその補体介在性障害を治療するための医学的使用 |
| EP4059949A1 (en) | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| CN117106745B (zh) * | 2022-06-01 | 2025-02-14 | 北京擎科生物科技股份有限公司 | 逆转录突变体及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030228616A1 (en) * | 1999-10-29 | 2003-12-11 | Stratagene | DNA polymerase mutants with reverse transcriptase activity |
| EP2029620B1 (en) * | 2006-05-26 | 2016-05-25 | Waikatolink Limited | Ob fold domains |
| ATE542830T1 (de) * | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| ES2836948T3 (es) * | 2008-11-03 | 2021-06-28 | Molecular Partners Ag | Proteínas de unión que inhiben la interacción del receptor de VEGF-A |
| US20110098216A1 (en) * | 2009-10-22 | 2011-04-28 | Regen Therapeutics Plc | Therapeutic uses of colostrinin |
| EP2469278A1 (en) * | 2010-12-21 | 2012-06-27 | Institut Pasteur | Reagentless fluorescent biosensors from nanofitins, rational design methods to create reagentless fluorescent biosensors and methods of their use |
| FR2974816A1 (fr) * | 2011-05-04 | 2012-11-09 | Centre Nat Rech Scient | Methode de generation de proteines |
| FR3004650B1 (fr) * | 2013-04-22 | 2015-05-29 | Affilogic | Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation |
| FR3027521B1 (fr) * | 2014-10-24 | 2016-12-16 | Affilogic | Compositions pour administration par voie orale |
| PL412787A1 (pl) * | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
| US20190167576A1 (en) * | 2016-09-08 | 2019-06-06 | The Board Of Trustees Of The Leland Stanford Junior University | Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue |
| EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| EP3632924A1 (en) * | 2018-10-07 | 2020-04-08 | Affilogic | Binders for inhibiting formation of multimeric proteins |
| EP3878858A1 (en) * | 2020-03-11 | 2021-09-15 | Affilogic | Variants of sac7d and their use in cancer therapy |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
-
2013
- 2013-04-22 FR FR1353662A patent/FR3004650B1/fr not_active Expired - Fee Related
-
2014
- 2014-04-22 CN CN202010402321.XA patent/CN111467477A/zh active Pending
- 2014-04-22 WO PCT/EP2014/058139 patent/WO2014173899A1/fr not_active Ceased
- 2014-04-22 CN CN201480030115.3A patent/CN105338995B/zh active Active
- 2014-04-22 JP JP2016509434A patent/JP2016518379A/ja active Pending
- 2014-04-22 EP EP14718621.7A patent/EP2988766B1/fr active Active
- 2014-04-22 ES ES14718621.7T patent/ES2637421T3/es active Active
- 2014-04-22 US US14/786,287 patent/US10548945B2/en active Active
-
2019
- 2019-02-12 JP JP2019022358A patent/JP2019112410A/ja active Pending
- 2019-12-24 US US16/726,305 patent/US10898542B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518379A5 (enExample) | ||
| Chaulagain et al. | Passive delivery of protein drugs through transdermal route | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| EP4269560A3 (en) | Modified epidermal growth factor receptor peptides for use in genetically-modified cells | |
| WO2018187613A3 (en) | Anti-icos agonist antibodies and uses thereof | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| CA2807942C (en) | Erythrocyte-binding therapeutics | |
| EA202191027A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| JP2019507582A5 (enExample) | ||
| WO2007119011A3 (fr) | Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet | |
| WO2019241893A3 (en) | Anti-her3 antibody and uses thereof | |
| WO2017066132A3 (en) | Synthetic antibody mimic peptides | |
| MX2021001305A (es) | Anticuerpos anti-cxcr2 y usos de los mismos. | |
| US20160143990A1 (en) | Topical Compositions Comprising OB-Fold Variants | |
| MX2019002664A (es) | Proteina de union a antigeno contra her3. | |
| BR112022014574A2 (pt) | Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença | |
| HRP20161096T1 (hr) | Antigenski vežući proteini specifični za komponentu p serumskog amiloida | |
| MX2019001136A (es) | Partículas similares a virus con recubrimiento de alta densidad para inducir la expresión de anticuerpos. | |
| WO2014144768A3 (en) | Bh4 stabilized peptides and uses thereof | |
| JP2015187119A5 (enExample) | ||
| WO2023150724A3 (en) | Antigen binding proteins that bind b7-h3 | |
| JP2018500879A5 (enExample) | ||
| Kang et al. | Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide | |
| Fernández et al. | Recent developments in engineering and delivery of protein and antibody therapeutics | |
| EA202190572A1 (ru) | Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы |